J&

Johnson & Johnson(JNJ)

NEW BRUNSWICK, NJ
Pharmaceutical2 H-1B visas (FY2023)
WebsiteLinkedIn
OncologyImmunologyNeuroscienceCardiovascularInfectious Disease
Funding Stage
PUBLIC
Employees
131,900
Open Jobs
1798

Products & Portfolio (15)

35 discontinued products not shown

AKEEGA
niraparib tosylate monohydrate and abiraterone acetate
Growth
ORAL · TABLET
enzymes, including PARP-1 and PARP-2, that play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death. Increased niraparib‑induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2 . Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient‑derived xenograft tumor models with homologous recombination deficiency (HRD) that had either mutated or wild-type BRCA1/2 . Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis. CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity. DHEA and androstenedione are androgens and are precursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals [see ] . Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor. Abiraterone decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of abiraterone on serum testosterone levels. Changes in serum prostate specific antigen (PSA) levels may be observed but have not been shown to correlate with clinical benefit in individual patients. In mouse xenograft models of prostate cancer, the combination of niraparib and abiraterone acetate increased anti-tumor activity when compared to either drug alone.
suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC)prostate cancer
2023
0
BALVERSA
erdafitinib
Peak
ORAL · TABLET
Fibroblast Growth Factor Receptor Inhibitors
metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed onafter at least one line of prior systemic therapy
2019
0
CONCERTA
methylphenidate hydrochloride
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
(CNS) stimulant. The mode of therapeutic action of methylphenidate in the treatment of ADHD is not known. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.
attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old
2000
30
DARZALEX
daratumumab
Peak
mAbINJECTION · INJECTABLE
CD38-directed Antibody Interactions
dexamethasone in newly diagnosed patientsrefractory multiple myelomamelphalan+7 more
2015
30
DARZALEX FASPRO
daratumumab and hyaluronidase-fihj (human recombinant)
Peak
mAbINJECTION · INJECTABLE
CD38-directed Antibody Interactions
lenalidomidedexamethasone for inductionconsolidation in newly diagnosed patients+12 more
2020
30
EDURANT
rilpivirine hydrochloride
LOE Approaching
ORAL · TABLET
12.1 Mechanism of Action Rilpivirine is an antiviral drug [see ] . 12.2 Pharmacodynamics Effects on Electrocardiogram The effect of EDURANT at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady state. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction was 2.0 (5.0) milliseconds (i.e., below the threshold of clinical concern). When doses of 75 mg once daily and 300 mg once daily of EDURANT (3 times and 12 times the dose in EDURANT) were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction were 10.7 (15.3) and 23.3 (28.4) milliseconds, respectively. Steady-state administration of EDURANT 75 mg once daily and 300 mg once daily resulted in a mean steady-state C max approximately 2.6-fold and 6.7-fold, respectively, higher than the mean C max observed with the recommended 25 mg once daily dose of EDURANT [see ] . 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of rilpivirine have been evaluated in adult healthy subjects and in adult antiretroviral treatment-naïve HIV-1-infected subjects. Exposure to rilpivirine was generally lower in HIV-1 infected subjects than in healthy subjects. Table 7: Pharmacokinetic Estimates of Rilpivirine 25 mg Once Daily in Antiretroviral Treatment-Naïve HIV-1-Infected Adult Subjects (Pooled Data from Phase 3 Trials through Week 96) Parameter Rilpivirine 25 mg once daily N=679 AUC 24h (ng∙h/mL) Mean±Standard Deviation 2235±851 Median (Range) 2096 (198 – 7307) C 0h (ng/mL) Mean±Standard Deviation 79±35 Median (Range) 73 (2 – 288) Absorption and Bioavailability After oral administration, the maximum plasma concentration of rilpivirine is generally achieved within 4–5 hours. The absolute bioavailability of EDURANT and EDURANT PED is unknown. Effects of Food on Oral Absorption The exposure to rilpivirine was approximately 40% lower when EDURANT was taken in a fasted condition as compared to a normal caloric meal (533 kcal) or high-fat high-caloric meal (928 kcal). When EDURANT was taken with only a protein-rich nutritional drink, exposures were 50% lower than when taken with a meal. Administration of the EDURANT PED 2.5 mg tablets dispersed in drinking water in fasted conditions or after yogurt consumption resulted in a 31% and 28% lower exposure, respectively, compared to administration in fed conditions (a meal containing 533 kcal) in adults. Distribution Rilpivirine is approximately 99.7% bound to plasma proteins in vitro , primarily to albumin. The distribution of rilpivirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans. Metabolism In vitro experiments indic
human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 2 years of ageolderweighing at least 14 kg with plasma HIV-1 RNA less than+14 more
2011
25
EDURANT PED
rilpivirine hydrochloride
Growth
ORAL · TABLET, FOR SUSPENSION
12.1 Mechanism of Action Rilpivirine is an antiviral drug [see ] . 12.2 Pharmacodynamics Effects on Electrocardiogram The effect of EDURANT at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady state. The maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction was 2.0 (5.0) milliseconds (i.e., below the threshold of clinical concern). When doses of 75 mg once daily and 300 mg once daily of EDURANT (3 times and 12 times the dose in EDURANT) were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline-correction were 10.7 (15.3) and 23.3 (28.4) milliseconds, respectively. Steady-state administration of EDURANT 75 mg once daily and 300 mg once daily resulted in a mean steady-state C max approximately 2.6-fold and 6.7-fold, respectively, higher than the mean C max observed with the recommended 25 mg once daily dose of EDURANT [see ] . 12.3 Pharmacokinetics Pharmacokinetics in Adults The pharmacokinetic properties of rilpivirine have been evaluated in adult healthy subjects and in adult antiretroviral treatment-naïve HIV-1-infected subjects. Exposure to rilpivirine was generally lower in HIV-1 infected subjects than in healthy subjects. Table 7: Pharmacokinetic Estimates of Rilpivirine 25 mg Once Daily in Antiretroviral Treatment-Naïve HIV-1-Infected Adult Subjects (Pooled Data from Phase 3 Trials through Week 96) Parameter Rilpivirine 25 mg once daily N=679 AUC 24h (ng∙h/mL) Mean±Standard Deviation 2235±851 Median (Range) 2096 (198 – 7307) C 0h (ng/mL) Mean±Standard Deviation 79±35 Median (Range) 73 (2 – 288) Absorption and Bioavailability After oral administration, the maximum plasma concentration of rilpivirine is generally achieved within 4–5 hours. The absolute bioavailability of EDURANT and EDURANT PED is unknown. Effects of Food on Oral Absorption The exposure to rilpivirine was approximately 40% lower when EDURANT was taken in a fasted condition as compared to a normal caloric meal (533 kcal) or high-fat high-caloric meal (928 kcal). When EDURANT was taken with only a protein-rich nutritional drink, exposures were 50% lower than when taken with a meal. Administration of the EDURANT PED 2.5 mg tablets dispersed in drinking water in fasted conditions or after yogurt consumption resulted in a 31% and 28% lower exposure, respectively, compared to administration in fed conditions (a meal containing 533 kcal) in adults. Distribution Rilpivirine is approximately 99.7% bound to plasma proteins in vitro , primarily to albumin. The distribution of rilpivirine into compartments other than plasma (e.g., cerebrospinal fluid, genital tract secretions) has not been evaluated in humans. Metabolism In vitro experiments indic
human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients 2 years of ageolderweighing at least 14 kg with plasma HIV-1 RNA less than+14 more
2024
0
ELMIRON
pentosan polysulfate sodium
LOE Approaching
ORAL · CAPSULE
CLINICAL PHARMACOLOGY General Pentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects. The mechanism of action of pentosan polysulfate sodium in interstitial cystitis is not known. Pharmacokinetics Absorption In a clinical pharmacology study in which healthy female volunteers received a single oral 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug as a solution under fasted conditions, maximal levels of plasma radioactivity were seen approximately at a median of 2 hours (range 0.6-120 hours) after dosing. Based on urinary excretion of radioactivity, a mean of approximately 6% of a radiolabeled oral dose of pentosan polysulfate sodium is absorbed and reaches the systemic circulation. Food Effects: In clinical trials, ELMIRON was administered with water 1 hour before or 2 hours after meals; the effect of food on absorption of pentosan polysulfate sodium is not known. Distribution Preclinical studies with parenterally administered radiolabeled pentosan polysulfate sodium showed distribution to the uroepithelium of the genitourinary tract with lesser amounts found in the liver, spleen, lung, skin, periosteum, and bone marrow. Erythrocyte penetration is low in animals. Metabolism The fraction of pentosan polysulfate sodium that is absorbed is metabolized by partial desulfation in the liver and spleen, and by partial depolymerization in the kidney to a large number of metabolites. Both the desulfation and depolymerization can be saturated with continued dosing. Excretion Following administration of an oral solution of a 300 or 450 mg dose of pentosan polysulfate sodium containing radiolabeled drug to groups of healthy subjects, plasma radioactivity declined with mean half-lives of 27 and 20 hours, respectively. A large proportion of the orally administered dose of pentosan polysulfate sodium (mean 84% in the 300 mg group and 58% in the 450 mg group) is excreted in feces as unchanged drug. A mean of 6% of an oral dose is excreted in the urine, mostly as desulfated and depolymerized metabolites. Only a small fraction of the administered dose (mean 0.14%) is recovered as intact drug in urine. Special Populations The pharmacokinetics of pentosan polysulfate sodium has not been studied in geriatric patients or in patients with hepatic or renal impairment. See also . Drug-Drug Interactions In a study in which healthy subjects received pentosan polysulfate sodium 100 mg capsule or placebo every 8 hours for 7 days, and were titrated with warfarin to an INR of 1.4 to 1.8, the pharmacokinetic parameters of R-warfarin and S-warfarin were similar in the absence and presence of pentosan polysulfate sodium. INR for warfarin + placebo and warfarin + pentosan polysulfate sodium were comparable. See also on the use of ELMIRON in patients receiving other therapies with anticoagulant effects. Pharmacodynamics The mechanism by which pentosan polysulfate sodium achieves its effe
1996
30
ERLEADA
apalutamide
Peak
ORAL · TABLET
(AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. A major metabolite, N-desmethyl apalutamide, is a less potent inhibitor of AR, and exhibited one-third the activity of apalutamide in an in vitro transcriptional reporter assay. Apalutamide administration caused decreased tumor cell proliferation and increased apoptosis leading to decreased tumor volume in mouse xenograft models of prostate cancer.
prostate cancer
2018
0
IBUPROFEN
ibuprofen
Post-LOE
SMORAL · TABLET
1994
30
IMAAVY
nipocalimab
Launch
GeneINJECTION · INJECTABLE
Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.
generalized myasthenia gravis (gMG) in adultolderanti-muscle-specific tyrosine kinase (MuSK) antibody positive
2025
30
INLEXZO
gemcitabine intravesical
Launch
INTRAVESICAL · SYSTEM
Nucleic Acid Synthesis Inhibitors
2025
0
View all 15 products

Pipeline & Clinical Trials

Cheetah System
Myopia
N/A
Clinical Trials (1)
NCT04200898Clinical Investigation of the Cheetah System For The Correction of Myopia With and Without Astigmatism
N/A
TEST Contact Lens
Visual Acuity
N/A
Clinical Trials (3)
NCT02756078Clinical Performance Evaluation of Two Silicone Hydrogel Lenses
N/A
NCT02699593Clinical Evaluation of Approved Contact Lenses
N/A
NCT02394925Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes
N/A
Mouth Rinse 19668-012
Gingivitis
N/A
Clinical Trials (1)
NCT01821261A Clinical Trial to Test the Effect of an Experimental Mouth Rinse on Gum Disease
N/A
Group and 1:1 occupational therapy sessions
Occupational Deprivation
N/A
Clinical Trials (1)
NCT07035210Impact of Self-directed Goals for Long-term Patients in a Forensic Hospital: A Mixed-Methods Pilot Study
N/A
N/A
Clinical Trials (5)
NCT00220714PREvent First Episode Relapse (PREFER)
Phase 4
NCT02558660Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients
N/A
NCT02600741Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
N/A

+2 more

N/A
Clinical Trials (2)
NCT04885296Evaluation of Prototype Lenses With Experimental UV/HEV Blocker
N/A
NCT05021081Visual Performance of Senofilcon A With and Without a New UV/HEV-filter
N/A
Nutritional Beverage
Concentration
N/A
Clinical Trials (2)
NCT01174134The Effects of Study Products Containing Varying Quantities of Docosahexaenoic Acid (DHA)
N/A
NCT01355601Effect of Carbohydrates From Nutritional Beverages in Children
N/A
ELITA System
Refractive Error
N/A
Clinical Trials (1)
NCT05713253A PHASED, PROSPECTIVE, MULTI-CENTER STUDY OF THE ELITA SYSTEM
N/A
JJVC Investigational Multifocal Contact Lens
Visual Acuity
N/A
Clinical Trials (4)
NCT04310566Evaluation of a Daily Disposable Novel Multifocal Contact Lens in a Myopic Population
N/A
NCT04995055Evaluation of Multifocal Contact Lens Designs With and Without an HEV Blocker on Visual Function
N/A
NCT05258149Comparison of a Silicone Hydrogel Daily Disposable Multifocal Contact Lens to a Marketed Product
N/A

+1 more

N/A
Clinical Trials (1)
NCT05996419Intervention to Reduce Safety Behaviors
N/A
Feeback group
Adult Smokers
N/A
Clinical Trials (1)
NCT00529256Evaluation of Organisational Changes to Promote Smoking Cessation
N/A
Observational pain control study
Pain
N/A
Clinical Trials (1)
NCT00771212Observational Study on the Patients With Pain Medications
N/A
Vistakon Investigational Multi-Purpose Solution II
Contact Lens Wear
N/A
Clinical Trials (1)
NCT01055457Vistakon Investigational Multi-purpose Contact Lens Care Solution.
N/A
etafilcon A
Visual Acuity
N/A
Clinical Trials (5)
NCT03388138Clinical Evaluation of Etafilcon A With Ketotifen
Phase 2
NCT01437319Mucin Balls and Corneal Inflammation Events
Phase 1/2
NCT03059810Clinical Evaluation of Investigational Multifocal Contact Lenses
N/A

+2 more

INFUSE® One Day Multifocal
Visual Acuity
N/A
Clinical Trials (1)
NCT07076160Pilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
N/A
Follow-up Study After Bankart Repair Using MG-1
Shoulder Dislocation
N/A
Clinical Trials (1)
NCT02228226Follow-up Study After Bankart Repair Using MG-1
N/A
Moisturizer Body Lotion
Atopic Dermatitis
N/A
Clinical Trials (1)
NCT05062213A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion in Adults of Atopic Dermatitis.
N/A
Colgate® Regular Cavity Protection
Tooth Stain
N/A
Clinical Trials (1)
NCT02151058A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal
N/A
N/A
Clinical Trials (1)
NCT02895685Group Dynamics in Surgical Skill Training
N/A
bi-planer radiography
Femoro Acetabular Impingement
N/A
Clinical Trials (1)
NCT04418596Longitudinal Follow-up of Male Soccer Players Prone to Developing CAM Hip Deformity
N/A
An Evaluation of the Causes of Anemia in Patients With Heart Failure
Anemia
N/A
Clinical Trials (1)
NCT00834691An Evaluation of the Causes of Anemia in Patients With Heart Failure
N/A
Cartoon video describing study information notice
Information Disclosure
N/A
Clinical Trials (1)
NCT05341791Paper Versus Cartoon Video-based Administration of Study Information Notice for Participant Consent
N/A
Formula PD-F-7716
Inadequate Lubrication
N/A
Clinical Trials (1)
NCT01271036Safety Study of a Sensitive Sensual Touch and Personal Lubricant
N/A
N/A
Clinical Trials (1)
NCT06670404Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures
N/A
Infant formula
Healthy Term Infants
N/A
Clinical Trials (5)
NCT02719405Impact of Infant Formula on Resolution of Cow's Milk Allergy
Phase 2
NCT00712608The Evaluation of Cow's Milk Formula - Study B
N/A
NCT02481531Growth and Tolerance of Cow's Milk-Based Infant Formulas
N/A

+2 more

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and P
High Risk Localized Prostate Cancer
N/A
Clinical Trials (1)
NCT05303558A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy
N/A
Motivational Interviewing to Address Suicidal Ideation- Revised
Suicide, Attempted
N/A
Clinical Trials (1)
NCT05256940Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
N/A
N/A
Clinical Trials (5)
NCT00770666Combination Medications vs. Patch Alone for Medically-Ill Smokers
Phase 4
NCT01075659Early Effects of a New Oral Nicotine Replacement Product and NiQuitin™ Lozenge
Phase 2
NCT03398876A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers
Phase 1

+2 more

alphafilcon A toric
Ametropia
N/A
Clinical Trials (1)
NCT00630305Endothelial Bleb Response With Toric Lenses
N/A
senofilcon A contact lenses
Ametropia
N/A
Clinical Trials (5)
NCT03319212Clinical Characterization of Symptomatic Populations
N/A
NCT06161012Evaluation of Delefilcon A and Senofilcon A Daily Disposable Toric Soft Contact Lenses Over Two Weeks of Wear
N/A
NCT01990664Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses
N/A

+2 more

JJVC Investigational Multifocal Contact Lens
Visual Acuity
N/A
Clinical Trials (1)
NCT04794751Evaluation of Investigational Daily Disposable Multifocal Contact Lenses Produced With Different Manufacturing Processes
N/A
Amino Acid formula
Cow's Milk Allergy
N/A
Clinical Trials (1)
NCT01584245Evaluation of the Efficacy of an Amino Acid Based Formula in Infants
N/A
Tecnis Symfony Optiblue/Tecnis Symfony Optiblue Toric
Cataract
N/A
Clinical Trials (1)
NCT06567834Clinical Evaluation and Comparison of the Tecnis Symfony Optiblue and Tecnis Symfony IOLs
N/A
JJVC Investigational Contact Lens
Visual Acuity
N/A
Clinical Trials (1)
NCT04287036Objective Vision Evaluation of Two Cosmetic Contact Lenses
N/A
ACUVUE OASYS 1-Day for Astigmatism
Visual Acuity
N/A
Clinical Trials (3)
NCT06649019Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses
N/A
NCT05601544The Effects of Contact Lenses With UV/HEV-Filter on Visual Function
N/A
NCT05344560Evaluation of Toric Soft Contact Lenses Containing a Chromophore to Block High-Energy Visible Light
N/A
etafilcon A control lens
Refractive Ametropia
N/A
Clinical Trials (1)
NCT01484028Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens
N/A
senofilcon A
Myopia
N/A
Clinical Trials (5)
NCT03222037Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers
Phase 4
NCT03330275Evaluating the Impact of JJVC Senofilcon A - Based Contact Lens With New UV-blocker on Day and Night Driving Performance
Phase 2
NCT00975585Clinical Performance Comparison of Two Contact Lenses
N/A

+2 more

Experimental - Tampon with GML
Vaginal Microflora
N/A
Clinical Trials (1)
NCT00913523Clinical Evaluation of Effects of an Investigational Tampon on Vaginal Microflora
N/A
Fall Prevention Tool Kit prototype using a randomized design
Patient Falls
N/A
Clinical Trials (1)
NCT00675935Falls - Tailoring Interventions for Patient Safety
N/A
Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface
Healthy
N/A
Clinical Trials (1)
NCT00707291Characterization of the Edge of Soft Contact Lens and Its Interaction With Ocular Surface
N/A
Abiraterone Acetate
Prostate Neoplasms
N/A
Clinical Trials (5)
NCT02405858A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy
Phase 4
NCT03009981A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Phase 3
NCT03777982Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Phase 3

+2 more

Marketed Contact Lens
Tear Film Characteristics
N/A
Clinical Trials (5)
NCT02540122Pilot Clinical Evaluation of Approved Contact Lenses
Phase 1
NCT02760810Clinical Evaluation of An Approved Contact Lens
N/A
NCT02669095Clinical Evaluation of Approved and Investigational Contact Lenses
N/A

+2 more

Toric Multifocal etafilcon A with PVP
Visual Acuity
N/A
Clinical Trials (1)
NCT03713281Evaluation of a Toric Multifocal Contact Lens Manufactured in Etafilcon Material in a Low ADD Hyperopic Population
N/A
JJVC Marketed Contact Lens
Visual Acuity
N/A
Clinical Trials (1)
NCT03431441Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style
N/A
N/A
Clinical Trials (1)
NCT01819194Contact Lens Comfort Relative to Meibomian Gland Status
N/A
Professional medical interpreter
Language Discordance
N/A
Clinical Trials (1)
NCT01041014Cost Effectiveness of Language Services in Hospital Emergency Departments (EDs)
N/A
N/A
Clinical Trials (1)
NCT02952235Evaluation of Sunscreens Under Actual Use Conditions
N/A
Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula
Allergy
N/A
Clinical Trials (1)
NCT00740974Allergy and Asthma Following Children Who Were Fed Supplemented Infant Formula
N/A
N/A
Clinical Trials (5)
NCT05502289Clinical Evaluation of Delefilcon A and Verofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
N/A
NCT05427539Feasibility Evaluation of Daily Disposable Toric Soft Contact Lenses Manufactured With an Alternative Hydration Process
N/A
NCT06778057Clinical Performance of Three Daily Disposable Silicone Hydrogel Contact Lenses
N/A

+2 more

Sunscreen A
Sunscreen
N/A
Clinical Trials (3)
NCT05565625A Study to Evaluate the Whitening Effect of Mineral Sunscreens in Multi-Cultural Skin Tones
N/A
NCT06734299A Study to Evaluate Usage of Mineral Sunscreens With Differentiated Whitening Attributes in Multi-Cultural Skin Tones
N/A
NCT05972434A Study of Two Facial Sunscreens to Assess Its Effect in Improving Hydration, Skin Barrier Function, and Skin Tone Uniformity Under Controlled and Normal Conditions of Use on the Face by Adult Participants
N/A

Open Jobs (1798)

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Seattle, Washington, United States of America
Yesterday
$100K - $175K/yr

Physician Program Director, Los Angeles

Danvers, Massachusetts, United States of America
Yesterday
$132K - $212K/yr

J&J MedTech Neurovascular Senior Financial Analyst, R&D

Irvine, California, United States of America
Research & Development
Yesterday
$79K - $128K/yr

Senior Clinical Research Associate (Senior Site Manager)

Prague, Czechia
Clinical Operations
Yesterday

Lead Compliance Specialist

Madrid, Spain
Legal & IP
Yesterday

QA Operation Platform Lead

Yokneam, Haifa District, Israel
Quality
Yesterday

APAC Regulatory Affairs Manager

Singapore, Singapore
Regulatory Affairs
Yesterday

Research and Development Leadership Development Program (RDLDP)- 2026 Full-Time

Santa Clara, California, United States of America
Research & Development
Yesterday
From $100K/yr

Senior Medical Science Liaison, Dermatology - Indianapolis

Indianapolis, Indiana, United States
Medical Affairs
Yesterday
$137K - $236K/yr

Director Product Management - Hips

Raritan, New Jersey, United States of America
Yesterday
$150K - $259K/yr

Machine Operator

Anasco, Puerto Rico, United States of America
Yesterday

Oncology Sales Specialist (Seattle WA; Portland OR and Spokane WA) - Johnson & Johnson Innovative Medicine

Seattle, Washington, United States of America
Commercial
Yesterday
$99K - $186K/yr

Sr. Principal Engineer, Aseptic DP Compounding Owner – Aseptic DP Compounding

Wilson, North Carolina, United States of America
Engineering
Yesterday

Neuroscience Sales Specialist - Spokane, WA – Johnson & Johnson Innovative Medicine

Spokane, Washington, United States
Commercial
Yesterday
$79K - $128K/yr

Neuroscience Sales Specialist - Tampa, Florida - Johnson & Johnson Innovative Medicine

Tampa, Florida, United States of America
Commercial
Yesterday

Associate Clinical Consultant (m/w/d) Großraum Göttingen

Göttingen , Germany
Clinical Operations
Yesterday

Key Account Manager, Oncology

California (Any City)
Commercial
Yesterday
$102K - $177K/yr

Products Specialist Woundclousure Biosurgery - Flanders

Diegem, Flemish Brabant, Belgium
Yesterday

National Sales Manager oncology

Warsaw, Masovian, Poland
Commercial
Yesterday

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Detroit, Michigan, United States
Yesterday

Senior Manager, Strategic Capacity Management- Orthopaedics

Raynham, Massachusetts, United States of America
Yesterday

Analyst II, Clinical Data Manager

Titusville, New Jersey, United States of America
Clinical Operations
Yesterday
$92K - $148K/yr

Value Architecture & Engineering Lead

Titusville, New Jersey, United States of America
Engineering
Yesterday

Clinical Operations Manager

Irvine, California, United States of America
Clinical Operations
Yesterday
$117K - $201K/yr

Responsable de Développement Clinique, Orthopédie Prothétique - Île-de-France (H/F)

Issy-les-Moulineaux, France
Yesterday
View all 1798 open positions →
Interview Prep Quick Facts
Portfolio: 185 approved products, 196 clinical trials
Top TAs: Oncology, Neurology, Infectious Diseases
H-1B (2023): 2 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 1798 active jobs
Portfolio Health
Pre-Launch13 (7%)
Launch5 (3%)
Growth5 (3%)
Peak27 (15%)
LOE Approaching114 (62%)
Post-LOE21 (11%)
185 total products
Therapeutic Area Focus
Oncology
15 marketed806 pipeline
Neurology
16 marketed495 pipeline
Infectious Diseases
8 marketed240 pipeline
Immunology
3 marketed214 pipeline
Cardiovascular
7 marketed156 pipeline
Metabolic Diseases
3 marketed147 pipeline
Ophthalmology
101 pipeline
Respiratory
2 marketed85 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$85.2B6%
R&D Spend
$483M(1%)
Net Income
$35.2B
Cash
$24.1B
Source: SEC 10-K Filing

Hiring Trend

Actively Hiring
1798
Open Roles
+1560
Added
-234
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub